BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25278289)

  • 1. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
    Tourdot BE; Conaway S; Niisuke K; Edelstein LC; Bray PF; Holinstat M
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2644-50. PubMed ID: 25278289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
    Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
    Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
    Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
    Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
    J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
    Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
    Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin complements G(i)- but not G(q)-dependent pathways for integrin {alpha}(IIb){beta}(3) activation and platelet aggregation.
    Campus F; Lova P; Bertoni A; Sinigaglia F; Balduini C; Torti M
    J Biol Chem; 2005 Jul; 280(26):24386-95. PubMed ID: 15863506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race differences in platelet reactivity: is protease activated receptor 4 a predictor of response to therapy?
    Mumaw MM; Nieman MT
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2524-6. PubMed ID: 25411106
    [No Abstract]   [Full Text] [Related]  

  • 9. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets.
    Cifuni SM; Wagner DD; Bergmeier W
    Blood; 2008 Sep; 112(5):1696-703. PubMed ID: 18544684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets.
    Arachiche A; de la Fuente M; Nieman MT
    PLoS One; 2013; 8(2):e55740. PubMed ID: 23405206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
    French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
    J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
    Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
    J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
    Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
    Xiang B; Zhang G; Ren H; Sunkara M; Morris AJ; Gartner TK; Smyth SS; Li Z
    PLoS One; 2012; 7(12):e51037. PubMed ID: 23236426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
    Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
    Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis.
    Van Doren L; Nguyen N; Garzia C; Fletcher EK; Stevenson R; Jaramillo D; Kuliopulos A; Covic L
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):e33-e45. PubMed ID: 33267659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AlphaIIbbeta3-mediated outside-in signaling induced by the agonist peptide LSARLAF utilizes ADP and thromboxane A2 receptors to cause alpha-granule secretion by platelets.
    Cho MJ; Liu J; Pestina TI; Steward SA; Jackson CW; Gartner TK
    J Thromb Haemost; 2003 Feb; 1(2):363-73. PubMed ID: 12871512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway.
    Holinstat M; Voss B; Bilodeau ML; Hamm HE
    Mol Pharmacol; 2007 Mar; 71(3):686-94. PubMed ID: 17151288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.
    Cleator JH; Duvernay MT; Holinstat M; Colowick NE; Hudson WJ; Song Y; Harrell FE; Hamm HE
    J Pharmacol Exp Ther; 2014 Oct; 351(1):33-43. PubMed ID: 25052834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.
    Edelstein LC; Simon LM; Lindsay CR; Kong X; Teruel-Montoya R; Tourdot BE; Chen ES; Ma L; Coughlin S; Nieman M; Holinstat M; Shaw CA; Bray PF
    Blood; 2014 Nov; 124(23):3450-8. PubMed ID: 25293779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.